Patent intelligence · US
US 9962363
Mast cell stabilizers treatment for systemic disorders
Mast cell stabilizers treatment for systemic disorders
Patent details — US 9962363
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 8, 2018
- Expiration
- May 3, 2038
- Applicant
- Patara Pharma, LLC
- Claims
- 20
- CPC classes
- A61K, A61K31/277, A61K31/352, A61K31/4422
Quick answer
US 9962363 (Mast cell stabilizers treatment for systemic disorders) is held by Patara Pharma, LLC. Status: granted. Granted May 8, 2018. Expires May 3, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Patara Pharma, LLC
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/277, A61K31/352, A61K31/4422, A61K31/4535, A61K31/4741
More from Patara Pharma, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12383572
Administration of an anti-activin-a compound to a subject
granted -
US 11925663
Methods of managing tumor flare in adoptive immunotherapy
granted -
US 11541070
Administration of an anti-activin-A compound to a subject
granted -
US 9968586
Mast cell stabilizers treatment for systemic disorders
granted -
US 9707206
Mast cell stabilizers treatment for systemic disorders
granted -
US 9265749
Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
granted -
US 8501678
Variant activin receptor polypeptides and uses thereof
granted
Frequently asked questions
What is US patent 9962363?
US 9962363 (Mast cell stabilizers treatment for systemic disorders) is held by Patara Pharma, LLC. Status: granted. Granted May 8, 2018. Expires May 3, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9962363?
Patara Pharma, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 9962363 expire?
Our index shows an expiration date of May 3, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.